Analyst Price Targets — EDIT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 8:22 pm | — | Robert W. Baird | $6.00 | $2.32 | StreetInsider | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings |
| November 5, 2024 10:23 am | Gena Wang | Barclays | $5.00 | $3.12 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $5 at Barclays |
| October 23, 2024 6:36 am | Yanan Zhu | Wells Fargo | $9.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo |
| October 22, 2024 1:41 pm | Joel Beatty | Robert W. Baird | $10.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $10 at Baird |
| August 8, 2024 7:24 am | Joon Lee | Truist Financial | $12.00 | $4.24 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities |
| August 8, 2024 6:44 am | Greg Harrison | Bank of America Securities | $15.00 | $4.21 | StreetInsider | BofA Securities Upgrades Editas Medicine (EDIT) to Buy |
| May 30, 2024 6:02 am | Liisa Bayko | Evercore ISI | $7.00 | $5.10 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI |
| May 9, 2024 12:34 am | Matthew Harrison | Morgan Stanley | $7.00 | $5.04 | StreetInsider | Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight |
| September 28, 2023 4:38 pm | Dae Gon Ha | Stifel Nicolaus | $17.00 | $6.92 | StreetInsider | Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation' |
| December 13, 2022 1:10 pm | — | Citigroup | $11.00 | $9.96 | Benzinga | Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11 |
Latest News for EDIT
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 820,667 shares of the company's stock after selling 245,055 shares during the period. JPMorgan Chase
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.